Instrument Inactif

Autres langues Phosphagenics Limited Australian S.E.

Actions

AU000000POH7

Produits pharmaceutiques

Autres langues

26/08	Avecho Biotechnology Limited Reports Earnings Results for the Half Year Ended June 30, 2026
29/06	Avecho Biotechnology Limited Continues Recruitment for Phase III Insomnia Program Following Positive Interim Analysis
24/06	Avecho to Continue With Full Enrollment in Insomnia Trial After Positive Data Monitoring Board Recommendation; Shares Hit 5.5-Year High
25/05	Avecho Biotechnology Limited Announces Resignation of Non-Executive Director Matthew Mcnamara, Effective May 25, 2026
22/05	Avecho Biotechnology Receives AU$1.98 Million Under Australian R&D Tax Incentive Scheme
21/05	Avecho Biotechnology Completes Treatment Phase for Interim Analysis of Third-Phase Insomnia Trial
01/05	Avecho Biotechnology Limited Announces Change of Company Secretary, Effective May 1, 2026
27/02	Avecho Biotechnology Limited Reports Earnings Results for the Full Year Ended December 31, 2025
27/02	Avecho Biotechnology Limited Auditor Raises 'Going Concern' Doubt
23/10/25	Avecho Biotechnology raises A$2.5M via placement
28/08/25	Avecho Biotechnology Limited Reports Earnings Results for the Half Year Ended June 30, 2025
08/08/25	ASX Biggest Losers
29/07/25	Avecho Biotechnology Accelerates Insomnia Drug Trial Recruitment Following Sandoz Partnership
20/05/25	Avecho Says New Trial Sites Start Screening, Recruitment
28/03/25	Avecho Biotechnology Receives $3 Million Licensing Fee from Sandoz for Cannabidiol Product; Shares Jump 20%
27/03/25	Avecho Receives Usd 3M Upfront Payment from Sandoz Ag for License to Commercialise CBD for Insomnia in Australia
07/03/25	Avecho Biotechnology's 2024 Loss Narrows as Revenue Rises; Shares Fall 14%
07/03/25	Avecho Biotechnology Limited Auditor Raises 'Going Concern' Doubt
03/03/25	Avecho Signs Licensing Agreement with Swiss Off-Patient Medicine Provider
03/03/25	Avecho And Sandoz Enter Exclusive License And Development Agreement
28/02/25	Avecho Biotechnology Seeks Trading Halt Pending Release Of Information About License And Development Agreement
27/02/25	Avecho Biotechnology Limited Reports Earnings Results for the Full Year Ended December 31, 2024
02/01/25	ASX Biggest Gainers
18/11/24	Opthea Appoints Kathy Connell to Board of Directors
26/08/24	Avecho Biotechnology Limited Reports Earnings Results for the Half Year Ended June 30, 2024